- Imagion Biosystems (IBX) has entered a trading halt as it plans and executes a capital raise
- The healthcare company will remain in the halt until November 23 or when the announcement is made, whichever occurs first
- In early October, Imagion received Human Research Ethics Approval (HREC) for its MagSense HER2 phase one breast cancer study
- A week later, Geoff Hollis was appointed as the company’s new Chief Financial Officer, effective December 1
- He’ll replace Brian Conn, who left Imagion in August to take on another full-time CFO role
- Shares in IBX last traded for 12.5 cents on November 17
Imagion Biosystems (IBX) has entered a trading halt as it plans and executes a capital raise.
The healthcare company will remain in the halt until November 23 or when the announcement is made, whichever occurs first.
Imagion is yet to announce how much it is aiming to raise or what it will use the funding for.
In early October, Imagion received Human Research Ethics Approval (HREC) for its MagSense HER2 phase one study for breast cancer.
MagSense uses disease-specific targeting nanoparticles and highly sensitive detectors to find tumours and other diseased cells.
According to Imagion, it doesn’t use radiation, instead dispatching tiny bio-safe nanoparticles coated with tumour-targeting antibodies.
The company expects to begin the study sometime this quarter.
A week later, Geoff Hollis was appointed as the company’s new Chief Financial Officer, effective December 1.
He’ll replace Brian Conn, who left Imagion in August to take on another full-time CFO role.
Geoff was previously the CFO of Lifestyle Communities, where he played a key role in cash management and financing to facilitate growth, creating shareholder value, and reaching the ASX 300.
Shares in IBX last traded for 12.5 cents on November 17.